This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fareed, J. Articles by Hoppensteadt, D. Search for Related Content PubMed PubMed Citation Articles by Fareed, J. Articles by Hoppensteadt, D. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Pulmonary Embolism Social Bookmarking                         What's this?

Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?

Loyola University Medical Center, Maywood, Illinois, jfareed{at}lumc.edu

Walter Jeske, PhD

Loyola University Medical Center, Maywood, Illinois

Daniel Fareed, BS

Loyola University Medical Center, Maywood, Illinois

Melaine Clark, BS

Loyola University Medical Center, Maywood, Illinois

Rakesh Wahi, PhD

Loyola University Medical Center, Maywood, Illinois

Cafer Adiguzel, PhD

Loyola University Medical Center, Maywood, Illinois

Debra Hoppensteadt, PhD

Loyola University Medical Center, Maywood, Illinois

Low molecular weight heparins are replacing unfractionated heparin in a number of clinical indications because of their improved subcutaneous bioavailability and more predictable antithrombotic response. Clinical trials have demonstrated that low molecular weight heparins are at least as safe and effective as unfractionated heparin for the initial treatment of venous thromboembolism, and unfractionated heparin and warfarin for primary and secondary thromboprophylaxis. The mechanism behind the antithrombotic action of low molecular weight heparins is not fully understood but is likely to involve inhibition of coagulation factors Xa and IIa (thrombin), release of tissue-factor-pathway inhibitor, and inhibition of thrombin activatable fibrinolytic inhibitor. Different low molecular weight heparins have been shown to have various effects on coagulation parameters. Seven low molecular weight heparins are currently marketed worldwide, each demonstrated distinct chemical entities with unique pharmacokinetic and pharmacodynamic profiles. Each low molecular weight heparin is approved for specific indications based on the available efficacy and safety data for that product. The relative efficacy and safety of the low molecular weight heparins are unclear because there have been very few direct comparisons in randomized clinical trials. While recommending low molecular weight heparins for the prevention and treatment of venous thromboembolism, clinical guidelines have not specified individual agents. National and international organizations recognize that low molecular weight heparins are distinct entities and that they should not be used interchangeably in clinical practice. Each low molecular weight heparin should be used at the recommended dose when efficacy and safety data exist for the condition being treated. When these data are not available, the dosing and administration of low molecular weight heparins must be adapted from existing data and recommendations.

Key Words: deep vein thrombosis • low molecular weight heparins • pulmonary embolism • thromboprophylaxis • venous thromboembolism

Clinical and Applied Thrombosis/Hemostasis, Vol. 14, No. 4, 385-392 (2008)
DOI: 10.1177/1076029608319881


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?